65 YEARS OF THE DOUBLE HELIX: Genetics informs precision practice in the diagnosis and management of pheochromocytoma
Open Access
- 1 August 2018
- journal article
- review article
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 25 (8) , T201-T219
Abstract
Although the authors of the present review have contributed to genetic discoveries in the field of pheochromocytoma research, we can legitimately ask whether these advances have led to improvements in the diagnosis and management of patients with pheochromocytoma. The answer to this question is an emphaticYes! In the field of molecular genetics, the well-established axiom that familial (genetic) pheochromocytoma represents 10% of all cases has been overturned, with >35% of cases now attributable to germline disease-causing mutations. Furthermore, genetic pheochromocytoma can now be grouped into five different clinical presentation types in the context of the ten known susceptibility genes for pheochromocytoma-associated syndromes. We now have the tools to diagnose patients with genetic pheochromocytoma, identify germline mutation carriers and to offer gene-informed medical management including enhanced surveillance and prevention. Clinically, we now treat an entire family of tumors of the paraganglia, with the exact phenotype varying by specific gene. In terms of detection and classification, simultaneous advances in biochemical detection and imaging localization have taken place, and the histopathology of the paraganglioma tumor family has been revised by immunohistochemical-genetic classification by gene-specific antibody immunohistochemistry. Treatment options have also been substantially enriched by the application of minimally invasive and adrenal-sparing surgery. Finally and most importantly, it is now widely recognized that patients with genetic pheochromocytoma/paraganglioma syndromes should be treated in specialized centers dedicated to the diagnosis, treatment and surveillance of this rare neoplasm.Keywords
This publication has 122 references indexed in Scilit:
- Next-generation sequencing in the clinical genetic screening of patients with pheochromocytoma and paragangliomaEndocrine Connections, 2013
- MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and ParagangliomaClinical Cancer Research, 2012
- Recent advances in the genetics of SDH-related paraganglioma and pheochromocytomaFamilial Cancer, 2010
- SDHA is a tumor suppressor gene causing paragangliomaHuman Molecular Genetics, 2010
- Germline mutations in TMEM127 confer susceptibility to pheochromocytomaNature Genetics, 2010
- SDH5 , a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in ParagangliomaScience, 2009
- The first Dutch SDHB founder deletion in paraganglioma – pheochromocytoma patientsBMC Medical Genetics, 2009
- The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressorGenes & Development, 2008
- Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma SyndromesThe Journal of Clinical Endocrinology & Metabolism, 2006
- A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in PheochromocytomasPLOS Genetics, 2005